Participants
death, allergy, MSSA, liver cirrhosis, non-type, active infection
CHRONIC HEART FAILURE, HYPERSENSITIVITY REACTION, PROSTHETIC VALVE ENDOCARDITIS, ALLERGY, LIVER CIRRHOSIS, HEART
Adult patients aged ≥18 years with at least one blood culture positive for MSSA ≤ 72 h before randomization, with evidence of active infection, were considered eligible for inclusion in the study. Treatment with any anti-staphylococcal antibiotic ≤72 h preceding randomization was allowed. Exclusion criteria were severe clinical status with expected death in <24 h; severe liver cirrhosis (Child–Pugh C); moderate-to-severe chronic heart failure (New York Heart Association functional classification, class III–IV); suspicion of prosthetic valve endocarditis; history of significant allergy to beta-lactam antibiotics or fosfomycin (defined as previous type 1 hypersensitivity reaction to any beta-lactam antibiotics or fosfomycin, or history of serious non-type 1 hypersensitivity reaction to any penicillin or fosfomycin); known non-susceptibility of 